Co-Diagnostics Soars 29% on Covid-19 Test Approval

By Kim Khan

Investing.com – Shares of Co-Diagnostics (NASDAQ:) soared into the close of trading Monday after the company said a test for Covid-19 received European regulatory approval.

The stock closed up nearly 29% at the closer of regular trading, and eased 0.8% postmarket.

The diagnostics company said its Logix Smart Coronavirus Covid-19 Test got regulatory clearance to be an in vitro diagnostic in markets that accept CE marking (European Community approval).

“Co-Diagnostics has received overwhelming interest in our novel coronavirus diagnostic from all over the world since first announcing its development a month ago,” Co-Diagnostics CEO Dwight Egan said in a statement.

“As the disease has spread from China, so have concerns about the global health community’s ability to contain and control it,” Egan said. “The first step in containment is a prompt, accurate diagnosis, and we are pleased to provide this product to those areas that are able to utilize a CE-marked IVD to protect their residents and visitors from a disease that has already affected millions.”

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.